<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Neurogen Corp. | Company News & Executive Profiles - NRGN | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/neurogen+corp..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Neurogen Corp.]]></description>
	<s:counts start="0" returned="8" found="8" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Neurogen Corporation Receives Extension from NASDAQ]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_23/ai_n30931955]]></link>
		<description><![CDATA[BRANFORD, Conn. -- Neurogen Corporation (NASDAQ: NRGN) announced today that it has been informed by The NASDAQ Stock Market that, pursuant to the NASDAQ's recently announced suspension of their requirements for minimum bid price and market value of publicly held shares, Neurogen's deadline to regain compliance with the NASDAQ's $1.00...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 23 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/compliance.html"><![CDATA[compliance]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/neurogen+corp..html"><![CDATA[Neurogen Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/readers.html"><![CDATA[Readers]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NRGN</category>
		<category domain="tickers">NDAQ,NRGN</category>
	</item>
	<item>
		<title><![CDATA[Neurogen Corporation Q2 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-223567.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Thank you. Operator instructions And our first question comes from the line of Kim Lee with Pacific Growth Equities. Please proceed. Kim Lee &#8211; Pacific Growth Equities  Good morning. Steve Davis  Good morning, Kim. Kim Lee &#8211; Pacific Growth Equities  Two questions. First,...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 02 Sep 2008 01:52:10 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/neurogen+corp..html"><![CDATA[Neurogen Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NRGN</category>
		<category domain="tickers">NRGN</category>
	</item>
	<item>
		<title><![CDATA[Neurogen Corporation Receives Notification from Nasdaq]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_August_27/ai_n28043139]]></link>
		<description><![CDATA[BRANFORD, Conn. -- Neurogen Corporation (Nasdaq: NRGN), a drug development company focused on improved drugs for psychiatric and neurological disorders, announced today that on August 26, 2008, it received notice from The Nasdaq Stock Market indicating that for the past 30 business days Neurogen's common stock has not met the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 27 Aug 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/compliance.html"><![CDATA[compliance]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/neurogen+corp..html"><![CDATA[Neurogen Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/readers.html"><![CDATA[READERS]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NRGN</category>
		<category domain="tickers">NDAQ,NRGN</category>
	</item>
	<item>
		<title><![CDATA[Neurogen Corporation Q1 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-226333.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions. You have a question from the line of Kim Lee of Pacific Growth Equities. Please proceed. Kim Lee - Pacific Growth Equities Good morning. Steve Davis Hi Kim. Kim Lee - Pacific Growth Equities Hi. A quick question, again, can you repeat what the weighted...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 30 May 2008 07:47:15 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/neurogen+corp..html"><![CDATA[Neurogen Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NRGN</category>
		<category domain="tickers">NRGN</category>
	</item>
	<item>
		<title><![CDATA[Neurogen Corporation's Auditors Expressed Going Concern Qualification]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_March_23/ai_n24943845]]></link>
		<description><![CDATA[BRANFORD, Conn. -- Neurogen Corporation (Nasdaq:NRGN) announced today that in its 2007 financial statements included in the Company's Annual Report on Form 10-K, the auditor's opinion contained a "going concern" qualification. NASDAQ's marketplace rules require NASDAQ-listed companies to publicly announce the receipt of an audit opinion containing a "going concern"...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Sun, 23 Mar 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/audit.html"><![CDATA[audit]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/neurogen+corp..html"><![CDATA[Neurogen Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NRGN</category>
		<category domain="tickers">NDAQ,NRGN</category>
	</item>
	<item>
		<title><![CDATA[Neurogen Corporation Q4 2007 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-229019.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator   Operator Instructions  Our first question comes from the line of Katherine Xu - Credit Suisse.  Katherine Xu - Credit Suisse  Stephen, I was just wondering with regards to the Phase 2/3 study of Ambien versus, or adipiplon versus Ambien CR there&#8217;s...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 19 Mar 2008 12:34:08 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/neurogen+corp..html"><![CDATA[Neurogen Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NRGN</category>
		<category domain="tickers">NRGN</category>
	</item>
	<item>
		<title><![CDATA[Neurogen Proprietary Insomnia Compound Data to Be Presented at Associated Professional Sleep Societies Annual Meeting]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_June_4/ai_n19188811]]></link>
		<description><![CDATA[BRANFORD, Conn. -- Neurogen Corporation (Nasdaq: NRGN) today announced that data from previous Phase 1 and Phase 2a clinical studies for NG2-73, the Company's lead compound for the treatment of insomnia, will be presented in three sessions at the SLEEP 2007 Annual Meeting of the Associated Professional Sleep Societies APSS...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 04 Jun 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/center+for+democracy+and+technology.html"><![CDATA[Center for Democracy and Technology]]></category>
		<category domain="http://resources.bnet.com/topic/minneapolis.html"><![CDATA[Minneapolis]]></category>
		<category domain="http://resources.bnet.com/topic/neurogen+corp..html"><![CDATA[Neurogen Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NRGN</category>
		<category domain="tickers">NRGN</category>
	</item>
	<item>
		<title><![CDATA[Neurogen Files Universal Shelf Registration Statement]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_May_29/ai_n27254497]]></link>
		<description><![CDATA[BRANFORD, Conn. -- Neurogen Corporation (Nasdaq: NRGN), a drug discovery and development company, announced today that it has filed a $100 million universal shelf registration statement on Form S-3 with the Securities and Exchange Commission SEC, which will permit it, from time to time, to offer and sell debt securities,...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 29 May 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/neurogen+corp..html"><![CDATA[Neurogen Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/r%2526d.html"><![CDATA[R&D]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[SECURITY]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NRGN</category>
		<category domain="tickers">NRGN</category>
	</item>
</channel>
</rss>
